13F

Investor

BML Capital Management, LLC

CIK 0001616824 · filed 2026-05-06 · SEC filing

13F book

$155.8M

Positions

15

3 new · 1 sold

Largest name

34.3%

Aclaris Therapeutics, Inc. · ACRS

Est. mark

$25.1M

Price effect on 12 names still held. Flow $17.4M.
NameTickerSharesValueWeightEst. markChange
Aclaris Therapeutics, Inc.ACRS14.3M$53.4M34.3%$10.5MHeld
Atea Pharmaceuticals, Inc.AVIR7.06M$38M24.4%$12.8MCut$11.2M
Oramed Pharmaceuticals Inc.ORMP3.17M$10.8M6.9%$1.74MHeld
Tillys Inc2.15M$8.71M5.6%New
Outset Med Inc1.9M$7.3M4.7%$70.6KAdded$5.29M
PMV Pharmaceuticals, Inc.PMVP5.32M$6.6M4.2%−$52.9KAdded−$18.2K
Carmax IncKMX155K$6.44M4.1%$455.7KHeld
Kezar Life Sciences Inc720.8K$5.35M3.4%$814.5KHeld
Instil Bio, Inc.TIL645.6K$5.32M3.4%−$1.78MHeld
Target CorpTGT37.5K$4.54M2.9%$879.4KHeld
Kraft Heinz CoKHC125K$2.81M1.8%New
Janux Therapeutics, Inc.JANX155K$2.15M1.4%New
Pliant Therapeutics, Inc.PLRX1.55M$1.95M1.3%$61.8KHeld
Connect Biopharma Hldgs Ltd408.9K$1.07M0.7%−$81.8KHeld
ImageneBio, Inc.IMA200.7K$1M0.6%−$336.3KAdded−$217.8K

Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.